N
BNGO icon

Natixis’s Bionano Genomics BNGO Stock Holding History

Natixis’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-42
Closed -$4.72K – 1025
2023
Q4 		$4.72K Hold
42
– – ﹤0.01% 969
2023
Q3 		$7.58K Hold
42
– – ﹤0.01% 903
2023
Q2 		$15.3K Buy
+42
New +$19K ﹤0.01% 913
2021
Q3 		– Sell
-263
Closed -$1.16M – 1200
2021
Q2 		$1.16M Buy
+263
New +$1.04M 0.01% 596

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Natixis's BNGO Position: Q1 2024 in Review

Natixis sold out of Bionano Genomics (BNGO) in Q1 2024, closing a stake of 42 shares — an estimated $4.72K sold.

Natixis first reported a position in BNGO in Q2 2021 and held it in 4 quarters. The position peaked at $1.16M in Q2 2021. 55 funds tracked by Wall St. Rank hold BNGO as of Q1 2024.

  • Natixis reported no remaining Bionano Genomics position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 42 Bionano Genomics shares in Q1 2024, an estimated $4.72K.
  • Natixis first reported a position in Bionano Genomics in Q2 2021 and held it in 4 quarters.
  • Natixis's Bionano Genomics position peaked at $1.16M in Q2 2021.
  • 55 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.